Phosphodiesterase-5 inhibitors

Handbook of Experimental Pharmacology

Volumn 218, Issue , 2013, Pages 229-255

  Cockrill, Barbara A ^a   Waxman, Aaron B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cGMP; Guanyl cyclase; Phosphodiesterase 5; Sildenafil; Tadalafil

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; CYTOCHROME P450; NITRIC OXIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CARDIOPULMONARY HEMODYNAMICS; DIASTOLIC HEART FAILURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME DEGRADATION; EXERCISE; HEART FAILURE DUE TO REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; SIGNAL TRANSDUCTION; STROKE VOLUME;

EID: 84893042118     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-38664-0_10     Document Type: Article

References (97)

1. Abdel-Aziz AA, Asiri YA, El-Azab AS, Al-Omar MA, Kunieda T (2011) Tadalafil. Profiles Drug Subst Excip Relat Methodol 36:287-329
2. Administration. USFDA (2012) Revatio (sildenafil): Drug safety communication-recommendation against use in children
3. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K et al (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebocontrolled trial. Lancet 364(9431):347-354
4. Andersen CU, Mulvany MJ, Simonsen U (2005) Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. Eur J Pharmacol 510(1-2):87-96
5. Azzouni F, Abu samra K (2011) Are phosphodiesterase type 5 inhibitors associated with visionthreatening adverse events A critical analysis and review of the literature. J Sex Med 8 (10):2894-2903
6. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE et al (2012) A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatmentnaive children with pulmonary arterial hypertension. Circulation 125(2):324-334
7. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N (2008) Effects of 50-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: A double-blind, placebo-controlled clinical trial. J Card Fail 14(3):189-197
8. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R et al (2010) Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 181(3):270-278
9. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE et al (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134(1):44-54
10. Center for Drug Evaluation and Research (2000) Guidance document: Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on biopharmaceutics classification system. In: Department of Health and Human Services UFaDA (ed) Rockville, MD
11. Center for Drug Evaluation and Research (2003a) NDA 021400 Levitra (Vardenafil Hydrochloride) Tablets: Clinical Pharmacology/Biopharmaceutics Review. In: Department of Health and Human Services UFaDA (ed) Rockville, MD
12. Center for Drug Evaluation and Research (2003b) NDA 021368 Cialis (Tadalafil) Tablets: Clinical Pharmacology/Biopharmaceutics Review. In: Department of Health and Human Services UFaDA (ed) Rockville, MD
13. Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S et al (2011) A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 1(2):286-298
14. Chapman TH, Wilde M, Sheth A, Madden BP (2009) Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use Vascul Pharmacol 51(2-3):90-95
15. Chinkers M (1994) Targeting of a distinctive protein-serine phosphatase to the protein kinase-like domain of the atrial natriuretic peptide receptor. Proc Natl Acad Sci USA 91(23):11075-11079
16. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA (2007) Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131(3):897-899
17. Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG et al (2013) Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: Rationale and design. Eur J Heart Fail 15(1):119-122
18. Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: Target of sildenafil. J Biol Chem 274(20):13729-13732
19. Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56 (6):453-459
20. Corbin JD, Turko IV, Beasley A, Francis SH (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267(9):2760-2767
21. Corbin JD, Beasley A, Blount MA, Francis SH (2005) High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 334 (3):930-938
22. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU (2009) Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 64(10):883-888
23. Corte TJ, Gatzoulis MA, Parfitt L, Harries C, Wells AU, Wort SJ (2010) The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology 15 (8):1226-1232
24. Derbyshire ER, Marletta MA (2009) Biochemistry of soluble guanylate cyclase. Handb Exp Pharmacol (191):17-31
25. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA (2007) Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 49 (10):1079-1088
26. Francis SH, Corbin JD (1999) Cyclic nucleotide-dependent protein kinases: Intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36(4):275-328
27. Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52
28. Francis S, Zoraghi R, Kotera J, Ke H, Bessay E, Blount M et al (2006) Phosphodiesterase-5: Molecular characteristics relating to structure, function, and regulation. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC, Boca Raton, FL
29. Fukao M, Mason HS, Britton FC, Kenyon JL, Horowitz B, Keef KD (1999) Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072. J Biol Chem 274(16):10927-10935
30. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353(20):2148-2157
31. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al (2009a) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34(6):1219-1263
32. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z et al (2009b) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22):2894-2903
33. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N et al (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Lancet 360(9337):895-900
34. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA et al (2004a) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):68S-72S
35. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B et al (2004b) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J Am Coll Cardiol 44(7):1488-1496
36. Giaid A, Saleh D (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333(4):214-221
37. Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R (2010) Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil. Int J Cardiol 144(3):410-412
38. Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011a) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4(1):8-17
39. Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011b) Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124(2):164-174
40. Gupta M, Kovar A, Meibohm B (2005) The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45(9):987-1003
41. Helman DL Jr, Brown AW, Jackson JL, Shorr AF (2007) Analyzing the short-term effect of placebo therapy in pulmonary arterial hypertension: Potential implications for the design of future clinical trials. Chest 132(3):764-772
42. Hofmann F, Ammendola A, Schlossmann J (2000) Rising behind NO: CGMP-dependent protein kinases. J Cell Sci 113(10):1671-1676
43. Hofmann F, Bernhard D, Lukowski R, Weinmeister P (2009) cGMP regulated protein kinases (cGK). In: Schmidt HHW, Hofmann F, Stasch J-P (eds) cGMP: Generators, effectors and therapeutic implications. Springer, Heidelberg, pp 137-162
44. Holverda S, Rietema H, Bogaard HJ, Westerhof N, Postmus PE, Boonstra A et al (2008) Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther 21(3):558-564
45. Jing ZC, Jiang X, Wu BX, Xu XQ, Wu Y, Ma CR et al (2009) Vardenafil treatment for patients with pulmonary arterial hypertension: A multicentre, open-label study. Heart 95 (18):1531-1536
46. Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY et al (2011) Vardenafil in pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 183(12):1723-1729
47. Khan AS, Sheikh Z, Khan S, Dwivedi R, Benjamin E (2011) Viagra deafness-sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope 121(5):1049-1054
48. Klein T, Eltze M, Grebe T, Hatzelmann A, Komhoff M (2007) Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 75(2):390-397
49. Koller K, Lowe D, Bennett G, Minamino N, Kangawa K, Matsuo H et al (1991) Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 252(5002):120-123
50. Kotera J, Francis SH, Grimes KA, Rouse A, Blount MA, Corbin JD (2004) Allosteric sites of phosphodiesterase-5 sequester cyclic GMP. Front Biosci 9:378-386
51. Kruuse C, Rybalkin SD, Khurana TS, Jansen-Olesen I, Olesen J, Edvinsson L (2001) The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. Eur J Pharmacol 420(1):55-65
52. Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM et al (2012) Sildenafil for chronic obstructive pulmonary disease: A randomized crossover trial. COPD 9(3):268-275
53. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J et al (2007) Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116(14):1555-1562
54. Lin CS, Chow S, Lau A, Tu R, Lue TF (2001) Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: Identification of a critical Sp1-binding site. Biochem Biophys Res Commun 280(3):693-699
55. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G et al (2010) Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 121(13):1474-1483
56. Maclean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, Sweeney G (1997) Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension. J Pharmacol Exp Ther 283(2):619-624
57. Maddox PT, Saunders J, Chandrasekhar SS (2009) Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology. Laryngoscope 119(8):1586-1589
58. Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I et al (2009) Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: The effects of sildenafil. J Am Coll Cardiol 54(7):595-600
59. Muirhead GJ, Rance DJ, Walker DK, Wastall P (2002a) Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 53(Suppl 1):13S-20S
60. Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B (2002b) The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 53 (Suppl 1):21S-30S
61. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D (2003) Direct activation of PDE5 by cGMP: Long-term effects within NO/cGMP signaling. J Cell Biol 160 (5):719-727
62. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116(3):238-248
63. Nichols DJ, Muirhead GJ, Harness JA (2002) Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53(Suppl 1):5S-12S
64. Ogut O, Brozovich FV (2003) Regulation of force in vascular smooth muscle. J Mol Cell Cardiol 35(4):347-355
65. Oudiz RJ (2007) Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 28(1):233-241, x
66. Oudiz RJ, Brundage BH, Galie N, Ghofrani HA, Simonneau G, Botros FT et al (2012) Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 60(8):768-774
67. Prasad S, Wilkinson J, Gatzoulis MA (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343(18):1342
68. Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH (2007) Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev 15(2):76-86
69. Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter MM et al (2012) PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: Rationale and design. Circ Heart Fail 5(5):653-659
70. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N et al (2008) Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 31 (4):759-764
71. Rosen RC, Kostis JB (2003) Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 92(9):9-18
72. Rubin LJ, Badesch DB, Fleming TR, Galie N, Simonneau G, Ghofrani HA et al (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study. Chest 140(5):1274-1283
73. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277 (5):3310-3317
74. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003a) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93(4):280-291
75. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA (2003b) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22 (3):469-478
76. Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43(7):1149-1153
77. Schlossmann J, Desch M (2009) cGK substrates. In: Schmidt HHW, Hofmann F, Stasch J-P (eds) cGMP: Generators, effectors and therapeutic implications. Springer, Heidelberg, pp 163-193
78. Schlossmann J, Ammendola A, Ashman K, Zong X, Huber A, Neubauer G et al (2000) Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase I [beta]. Nature 404(6774):197-201
79. Schlossmann J, Feil R, Hofmann F (2003) Signaling through NO and cGMP-dependent protein kinases. Ann Med 35(1):21-27
80. Schulz S, Singh S, Bellet RA, Singh G, Tubb DJ, Chin H et al (1989) The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell 58(6):1155-1162
81. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR (2003) Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107 (25):3230-3235
82. Snodgrass AJ, Campbell HM, Mace DL, Faria VL, Swanson KM, Holodniy M (2010) Sudden sensorineural hearing loss associated with vardenafil. Pharmacotherapy 30(1):112
83. Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr Opin Cell Biol 12(2):174-179
84. Takatsuki S, Calderbank M, Ivy DD (2012) Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 33(5):683-688
85. Taleb M, Khuder S, Tinkel J, Khouri SJ (2013) The diagnostic accuracy of Doppler echocardiography in assessment of pulmonary artery systolic pressure: A meta-analysis. Echocardiography 30(3):258-265
86. Tay EL, Geok-Mui MK, Poh-Hoon MC, Yip J (2008) Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: A case series of 12 patients. Int J Cardiol 125(3):416-417
87. Teixeira CE, Priviero FBM, Webb RC (2006) Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 316 (2):654-661
88. Thomas MK, Francis SH, Beebe SJ, Gettys TW, Corbin JD (1992) Partial mapping of cyclic nucleotide sites and studies of regulatory mechanisms of phosphodiesterases using cyclic nucleotide analogues. Adv Second Messenger Phosphoprotein Res 25:45-53
89. Turko IV, Francis SH, Corbin JD (1998) Binding of cGMP to both allosteric sites of cGMPbinding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J 329(Pt 3):505-510
90. Vanderheyden V, Devogelaere B, Missiaen L, De Smedt H, Bultynck G, Parys JB (2009) Regulation of inositol 1,4,5-trisphosphate-induced Ca2+ release by reversible phosphorylation and dephosphorylation. Biochim Biophys Acta 1793(6):959-970
91. Waldman SA, Murad F (1988) Biochemical mechanisms underlying vascular smooth muscle relaxation: The guanylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol 12(Suppl 5): S115-S118
92. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P et al (1999) Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29 (3):297-310
93. Wirostko BM, Tressler C, Hwang LJ, Burgess G, Laties AM (2012) Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: Results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ 344:e554
94. Wyatt TA, Naftilan AJ, Francis SH, Corbin JD (1998) ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol 274(2 Pt 2):H448-H455
95. Zeng WJ, Sun YJ, Gu Q, Xiong CM, Li JJ, He JG (2012) Impact of sildenafil on survival of patients with idiopathic pulmonary arterial hypertension. J Clin Pharmacol 52(9):1357-1364
96. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Idiopathic Pulmonary Fibrosis Clinical Research Network et al (2010) A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363(7):620-628
97. Zoraghi R, Bessay EP, Corbin JD, Francis SH (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280(12):12051-12063